Member Info for Hurst10

Kyverna Therapeutics Announces Pricing of Upsized Initial Public Offering. More IPO activity with company shares being priced above range.

If we saw a therapeutic IPO , it would be snapped up. Perfect timing.

Avacta Therapeutics inc and its newsflow will no doubt attract a lot of attention.

Gene editing start-up Metagenomi and cancer specialist NeOnc Technologies have announced the terms of their initial public offerings, in another sign that investor interest in biotech is growing.The company has Moderna, Novo and Bayer among their backers.

This will be of relevance to Avacta's and Daewoong's JV : Affyxell and how the market could remind themselves of the upside in IPO valuation, now with Biocytogen gene editing on board as well.

Will be a great two months before AACR gathering.

Meanwhile Morphosys drops amid speculation Novartis could walk away from deal.

Has Novartis called Avacta?

Blow out numbers from Lilly and guiding higher.

Novo and Lilly heading for trillion dollar m/c

Feb 6 (Reuters) - Drugmaker Novartis AG (NOVN.S), opens new tab said it will acquire MorphoSys AG (MORG.DE), opens new tab, a developer of cancer treatments, for 2.7 billion euros ($2.9 billion), adding a promising rare bone-marrow cancer treatment candidate to its portfolio.

Reuters first reported on Monday that Switzerland-based Novartis was in advanced talks to acquire MorphoSys, leading to the German biotech firm's shares surging more than 40%.

Novartis in the lead to acquire cancer drug developer MorphoSys-sources

FYI:

Ref BCYC: book runners were Goldman Sachs & Co. LLC, Morgan Stanley and SVB Leerink acted as joint book-running managers for the offering. JMP Securities acted as co-manager for the offering.

With new head of Therapeutics in place at Avacta: she will be speaking to them.

From the company :

Fiona will continue to work with the Company through a transitionary period.

From Return and cancellations page on their website ref diagnostic business :

Avacta Life Sciences Limited

HOMEERROR 404: PAGE NOT FOUND

Sorry, but the page you were trying to view does not exist.

Watch the buy prints entering

Getting ready for Monday

Https://www.biopharmadive.com/news/lupus-cell-therapy-car-t-biotech-startups/705767/

A month into 2024, the tech IPO calendar remains blank. But after two years of quiet, biotech IPOs are suddenly making noise.

Last week, bladder cancer drug developer CG Oncology priced its IPO above the expected range and raised $380 million. Its shares then jumped 96% on the first day of trading. That offering was followed by Arrivent Biopharma, which raised $175 million and has traded up in price since its IPO.

Alto Neuroscience and Fractyl Health, two other biotech companies, are also planning imminent public debuts.

US listing of Avacta therapeutics next ? with newly appointed US based Head of Therapeutics ready to drive the AVA platform to a whole new valuation, all her friends at the major Pharma's at the upcoming AACR conference will all have their chequebooks ready!

Early NY start.

115-25 limit up

86,000 buy/sell prints going through at 115.159

Novartis earnings call started at 08.00 am NY time.

Precision medicine is the future.

The company have been saying.

Amazing what is being produced on the boards.

Just do your research, read the results being published, look what the majors are all saying.

Precision medicine

Gene therapy

AI

Several biotech stocks have done IPO's.

IPO's etc are all a gift at current levels.

They all require one thing: patience and being able to buy and wait.

You will all look clever very soon.

Upcoming conference in early April will have one theme only :M&A

Majors have cash, which one will act first.

Eli Lilly bought Point Pharma, which one is next.

Ignore the shorts, buy as much as you can at current levels, before they do.

Good luck

Novartis etc are reporting tomorrow.

Interesting last hour.

Size buyer's prints entering.

You cannot blame them, at current level it is a gift!

CG Oncology (CGON) kicked off biotech IPO season on a positive note, adding ~81% on its first day of trading on Thursday after upsizing its initial public offering twice from an initial value of $100M.